Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 24 results for emphysema

  1. Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) (TA965)

    NICE is unable to make a recommendation on human alpa1-proteinase inhibitor (Respreeza) for treating emphysema in adults. CSL Behring UK has confirmed that it does not intend to launch the product in England and Wales. The reasons for this decision are primarily related to the company’s inability to offer the product at a price to meet the current threshold of cost effectiveness.

    Sections for TA965

  2. Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)

    This guideline covers diagnosing and managing chronic obstructive pulmonary disease or COPD (which includes emphysema and chronic bronchitis) in people aged 16 and older. It aims to help people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce symptoms, improve quality of life and keep them healthy for longer.

  3. VIDAvision for lung volume analysis in emphysema (MIB148)

    NICE has developed a medtech innovation briefing (MIB) on VIDAvision for lung volume analysis in emphysema .

  4. Lung volume reduction surgery for advanced emphysema (IPG114)

    Evidence-based recommendations on lung volume reduction surgery for treating advanced emphysema. This involves removing damaged lung tissue using a special stapling device, a laser, or both.

  5. Bronchoscopic thermal vapour ablation for upper-lobe emphysema (IPG652)

    Evidence-based recommendations on bronchoscopic thermal vapour ablation for upper-lobe emphysema in adults. This involves using steam to destroy the diseased part of the lung.

  6. Endobronchial valve insertion to reduce lung volume in emphysema (IPG600)

    Evidence-based recommendations on endobronchial valve insertion to reduce lung volume in emphysema. This involves placing small one-way valves in some airways leading to damaged parts of the lungs.

  7. Insertion of endobronchial nitinol coils to improve lung function in emphysema (IPG517)

    Evidence-based recommendations on insertion of endobronchial nitinol coils to improve lung function in emphysema. This involves inserting coils to reduce airflow to damaged parts of the lung.

  8. Current evidence on the safety and efficacy of bronchoscopic thermal vapour ablation for upper-lobe emphysema is inadequate in quantity and quality. Therefore the procedure should only be used in the context of  research .

    safety and efficacy of bronchoscopic thermal vapour ablation for upper-lobe emphysema is inadequate in quantity and quality. Therefore...

  9. Use of a glue or sealant to achieve lung volume reduction in emphysema and lung cancer

    Register an interest in this interventional procedure   ...

  10. Emphysema - inhaled alpha-1 antitrypsin [ID1200]

    Discontinued [GID-TA11179]

  11. Bronchoscopic intrabullous autologous blood instillation (BIABI) for the therapy of Emphysema: intractable with pneumothorax, COPD & Lung cancer, patients requiring lung biopsy

    Register an interest in this interventional procedure   ...

  12. Endobronchial nerve ablation for chronic obstructive pulmonary disease (IPG714)

    Evidence-based recommendations endobronchial nerve ablation for chronic obstructive pulmonary disease. This involves destroying (ablating) the nerves on the outside of the airway (endobronchial nerves) to improve breathing.

  13. Nintedanib for treating idiopathic pulmonary fibrosis (TA379)

    Evidence-based recommendations on nintedanib (Ofev) for adults with idiopathic pulmonary fibrosis.

  14. Translaryngeal tracheostomy (IPG462)

    Evidence-based recommendations on translaryngeal tracheostomy (TLT). This involves passing a tube from inside the windpipe to outside the neck to aid breathing.

  15. The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)

    NICE has developed a Medtech Innovation Briefing (MIB) on the RhinoChill intranasal cooling system